Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy in first-line advanced malignant pleural mesothelioma
2018-002180-25Phase 3Completed
- Sponsor
- European Thoracic Oncology Platform
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of atezolizumab in pleural mesothelioma (2 arms), sponsored by European Thoracic Oncology Platform. Primary endpoint: overall-survival (OS). Started Nov 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2018-002180-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002180-25.